Lal Avtar, Veinot John P, Leenen Frans H H
Hypertension Unit, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario, Canada K1Y 4E9.
Cardiovasc Res. 2004 Dec 1;64(3):437-47. doi: 10.1016/j.cardiores.2004.08.004.
Oral administration of spironolactone improves cardiac remodeling and its central infusion prevents the increase in sympathetic drive post-myocardial infarction (MI). We hypothesized that central actions of aldosterone contribute to cardiac remodeling post-MI.
To compare the effects of intracerebroventricular (icv) infusion and oral administration of spironolactone on cardiac remodeling and left ventricle (LV) dysfunction post-MI in rats.
Spironolactone was administered orally (80 mg/kg/day) or by icv infusion (100 ng/h), starting 1-3 days post-MI in Wistar rats and continued for 6 weeks.
At 6 weeks post-MI, in the rats treated with vehicle, LV peak systolic pressure (LVPSP) and LV dP/dt max were clearly decreased and LV end diastolic pressure (LVEDP) and plasma catecholamines and serum aldosterone increased. All these parameters improved with both oral and icv spironolactone. The MI-induced increases in internal circumferences of LV and right ventricle (RV), and in interstitial and perivascular fibrosis, in both the LV and RV were significantly prevented/inhibited by both oral and icv spironolactone. Laminin, fibronectin and fibrillar collagen (visualized by scanning electron microscopy, SEM) increased in the non-infarcted part of the LV post-MI in the vehicle group, but not/less in rats on oral or icv spironolactone.
Since the magnitude of beneficial effects of icv spironolactone at low doses was largely equal to that achieved with its oral administration at much higher doses, we propose that in addition to other sites of action, aldosterone appears to activate central nervous system (CNS) pathways and thereby influences peripheral mechanisms involved in cardiac remodeling.
口服螺内酯可改善心脏重塑,其脑室内注射可预防心肌梗死后交感神经驱动的增加。我们推测醛固酮的中枢作用有助于心肌梗死后的心脏重塑。
比较脑室内注射和口服螺内酯对大鼠心肌梗死后心脏重塑和左心室功能障碍的影响。
在Wistar大鼠心肌梗死后1-3天开始,口服螺内酯(80毫克/千克/天)或脑室内注射(100纳克/小时),持续6周。
心肌梗死后6周,在给予赋形剂治疗的大鼠中,左心室收缩压峰值(LVPSP)和左心室dP/dt max明显降低,左心室舒张末期压力(LVEDP)、血浆儿茶酚胺和血清醛固酮升高。口服和脑室内注射螺内酯均可改善所有这些参数。口服和脑室内注射螺内酯均能显著预防/抑制心肌梗死引起的左心室和右心室(RV)内周长增加,以及左心室和右心室内间质和血管周围纤维化。在赋形剂组中,心肌梗死后左心室非梗死部分的层粘连蛋白、纤连蛋白和纤维状胶原(通过扫描电子显微镜,SEM观察)增加,但在口服或脑室内注射螺内酯的大鼠中未增加/增加较少。
由于低剂量脑室内注射螺内酯的有益作用程度与高剂量口服螺内酯的有益作用程度基本相当,我们认为除了其他作用部位外,醛固酮似乎还激活中枢神经系统(CNS)途径,从而影响参与心脏重塑的外周机制。